The Duke Nephrology Fellowship Curriculum has integrated a latest module focusing on post-COVID-19 kidney injury surveillance, launched in early 2026 to address rising global concerns about long-term renal sequelae following SARS-CoV-2 infection. Developed in collaboration with the Duke Clinical Research Institute and informed by longitudinal data from the NIH RECOVER Initiative, the curriculum trains fellows to identify, manage, and study chronic kidney disease (CKD) progression in recovered COVID-19 patients using biomarkers like urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). This initiative responds to emerging evidence that up to 30% of hospitalized COVID-19 patients develop acute kidney injury (AKI), with a significant subset experiencing persistent dysfunction months after recovery.
In Plain English: The Clinical Takeaway
- Even mild COVID-19 can lead to subtle, long-term kidney damage that may not show symptoms until years later.
- Routine urine and blood tests after infection can detect early signs of trouble, allowing timely intervention.
- Fellows are now trained to look for hidden kidney issues in post-COVID patients, improving early detection and care.
Understanding Post-COVID Kidney Injury: Mechanisms and Evidence
SARS-CoV-2 can directly infect kidney cells via the ACE2 receptor, triggering inflammation, microclotting, and podocyte injury — key drivers of proteinuria and declining eGFR. A 2025 study published in JASN found that patients with severe COVID-19 had a 40% higher risk of developing CKD stage 3 or worse within 12 months compared to uninfected controls, even after adjusting for comorbidities like diabetes and hypertension. The mechanism involves persistent endothelial dysfunction and complement-mediated thrombotic microangiopathy, particularly in individuals with APOL1 high-risk genotypes, which are more prevalent in populations of West African ancestry.
Geopolitical and Healthcare System Implications
In the United States, the FDA has not yet approved any specific therapy for preventing or treating long COVID-related kidney injury, though agents targeting complement activation (e.g., ravulizumab) are under investigation in Phase II trials. In contrast, the UK’s NHS has incorporated routine kidney function monitoring into its Long COVID service framework since late 2024, offering eGFR and UACR testing at 3 and 6 months post-infection across 89 specialist clinics. This divergence highlights disparities in post-acute care infrastructure, with the Duke curriculum aiming to bridge gaps by equipping nephrology fellows to advocate for standardized screening protocols in underserved regions.
Funding, Bias Transparency, and Expert Perspectives
The curriculum update was funded by a $2.3 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, awarded in 2024 to Duke University to enhance nephrology training in pandemic-era sequelae. No pharmaceutical industry funding influenced content development, ensuring alignment with unbiased clinical guidelines. Dr. Erika Lee, lead nephrologist at Duke and principal investigator of the NIDDK grant, emphasized the urgency of this training:
We’re seeing a silent wave of kidney dysfunction in young, otherwise healthy adults who had mild COVID-19 two years ago. Our fellows must be equipped to detect it early — before dialysis becomes inevitable.
Similarly, Dr. Ziyad Al-Aly, Chief of Research and Development at the VA St. Louis Health Care System and a leading voice in long COVID research, noted in a 2025 interview:
Kidney involvement in long COVID isn’t rare — it’s underdiagnosed. Ignoring it risks missing a major contributor to cardiovascular mortality in survivors.
Clinical Evidence Summary: Post-COVID Kidney Outcomes
| Study/Population | Key Finding | Source |
|---|---|---|
| Hospitalized COVID-19 patients (N=15,000, US) | 31% developed AKI; 15% had persistent eGFR decline at 6 months | JAMA Intern Med, 2022 |
| Non-hospitalized COVID-19 (N=89,000, Veterans Health Admin) | 25% higher risk of new-onset CKD at 6 months vs. Controls | JASN, 2021 |
| APOL1 high-risk subgroup (African ancestry, N=4,200) | 2.3x faster CKD progression post-COVID vs. Low-risk | Kidney Int, 2022 |
| RECOVER Initiative cohort (N=12,000, multisite) | 1 in 4 long COVID patients had abnormal UACR at 12 months | NIH RECOVER, 2024 |
| Phase II trial: Ravulizumab in post-AKI COVID-19 (N=120) | 40% reduction in proteinuria at 24 weeks (primary endpoint) | ClinicalTrials.gov, 2024 |
Contraindications & When to Consult a Doctor
There are no contraindications to monitoring kidney health after COVID-19; in fact, all recovered patients should undergo baseline assessment. Though, individuals with pre-existing CKD, diabetes, hypertension, or APOL1 high-risk variants should prioritize early screening. Patients should consult a nephrologist if they experience persistent foamy urine (suggesting proteinuria), swelling in legs or ankles, unexplained fatigue, or a sudden rise in blood pressure — signs that may indicate worsening kidney function. Immediate medical attention is warranted for decreased urine output, confusion, or nausea, which could signal acute kidney injury requiring urgent intervention.
As the Duke Nephrology Fellowship Curriculum advances into its second year, its focus on post-COVID renal surveillance exemplifies a translational model where clinical training evolves in real time to meet emerging public health threats. By integrating mechanistic understanding, equitable screening strategies, and evidence-based follow-up, the program aims not only to improve individual patient outcomes but also to inform national guidelines on long COVID management. The ultimate goal is clear: to transform a silent epidemic of organ damage into a detectable, treatable condition — before it becomes irreversible.
References
- Chawla et al. JAMA Intern Med. 2022;182(4):397-406. AKI and long-term kidney outcomes in hospitalized COVID-19 patients.
- Bowe et al. JASN. 2021;32(4):847-861. Kidney outcomes in non-hospitalized COVID-19 survivors.
- Pei et al. Kidney Int. 2022;101(5):1082-1093. APOL1 risk variants and COVID-19-associated kidney injury.
- NIH. RECOVER Initiative. Longitudinal study of post-acute sequelae of SARS-CoV-2 infection. Accessed April 2026.
- ClinicalTrials.gov. NCT05512345: Ravulizumab for persistent proteinuria post-AKI in COVID-19. Phase II trial. Sponsored by Alexion Pharmaceuticals.
